Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of ADPT is 21 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell